Syndax Pharmaceuticals SNDX Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's other income, net (note 6)?
- Syndax Pharmaceuticals (SNDX) reported other income, net (note 6) of -$186K in Q1 2026.
- How has Syndax Pharmaceuticals's other income, net (note 6) changed year-over-year?
- Syndax Pharmaceuticals's other income, net (note 6) increased by 15.8% year-over-year, from -$221K to -$186K.
- What is the long-term trend for Syndax Pharmaceuticals's other income, net (note 6)?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's other income, net (note 6) has grown at a 58.6% compound annual growth rate (CAGR), from $203K to -$1.28M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.